Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 7/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.30 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12263094 | 0.88 | RIPK1 (0.40) | RIPK1MDM2TP53P2RX7GRIA4 | |
| SCHEMBL15354521 | 0.84 | HRH3 (0.36) | HRH3RIPK1P2RX7HTR4 | |
| SCHEMBL2190251 | 0.76 | CALCRL (0.34) | HRH3RIPK1HTR4 | |
| SCHEMBL1274637 | 0.76 | CALCRL (0.34) | HRH3RIPK1HTR4 | |
| SCHEMBL12263102 | 0.71 | MDM2 (0.36) | RIPK1MDM2TP53P2RX7 | |
| SCHEMBL15354518 | 0.71 | RIPK1 (0.41) | RIPK1P2RX7GRIA4 | |
| SCHEMBL12263085 | 0.69 | CALCRL (0.41) | RIPK1MDM2TP53P2RX7GRIA4 | |
| SCHEMBL12263100 | 0.68 | CALCRL (0.40) | RIPK1MDM2TP53 | |
| SCHEMBL12921087 | 0.63 | CALCRL (0.41) | RIPK1 | |
| SCHEMBL1274728 | 0.63 | CALCRL (0.41) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569291-B2 | Bicyclic dihydroimidazolone CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20110224230-A1 | BICYCLIC DIHYDROIMIDAZOLONE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2011-09-15 | — | — | US | disclosed |
| US-20110224230-A1 | BICYCLIC DIHYDROIMIDAZOLONE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224230-A1 | BICYCLIC DIHYDROIMIDAZOLONE CGRP RECEPTOR ANTAGONISTS | BDKRB1, BDKRB2, CCKBR | HRH3 55/4885RIPK1 3516/4885MDM2 4695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.